Cargo
Lingyan Wang, DVM, PhD, currently serves as Principal Scientist at CARGO Therapeutics since July 2021. Prior to this, Lingyan worked at Seattle Children's as a Research Scientist III from March 2019 to July 2021, and at Oregon Health and Science University as a Research Associate from October 2009 to March 2019. Lingyan's research spans from using epigenetic modifiers to enhance anti-CD22 CAR-T function to targeting inner hair cells for hearing restoration. With a PhD in Veterinary Medicine from Jilin University and a DVM from Shandong Agricultural University, Lingyan's expertise is rooted in the biomedical field.
Cargo
1 followers
CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies.